(Q33596323)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10207690%20AND%20SRC:MED&resulttype=core&format=json

4 December 2019

review article

1 reference

title

Medical therapy for acromegaly (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10207690%20AND%20SRC:MED&resulttype=core&format=json

4 December 2019

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10207690%20AND%20SRC:MED&resulttype=core&format=json

4 December 2019

author name string

Newman CB

series ordinal

1

1 reference

28 July 2017

publication date

1 March 1999

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10207690%20AND%20SRC:MED&resulttype=core&format=json

Endocrinology and Metabolism Clinics of North America

4 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10207690%20AND%20SRC:MED&resulttype=core&format=json

4 December 2019

volume

28

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10207690%20AND%20SRC:MED&resulttype=core&format=json

4 December 2019

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10207690%20AND%20SRC:MED&resulttype=core&format=json

4 December 2019

page(s)

171-190

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10207690%20AND%20SRC:MED&resulttype=core&format=json

Consensus statement: benefits versus risks of medical therapy for acromegaly

4 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970062-1

7 January 2021

Epidemiology of acromegaly in the Newcastle region.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970062-1

7 January 2021

The effect of a new slow-release, long-acting somatostatin analogue, lanreotide, in acromegaly.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970062-1

7 January 2021

Treatment of acromegaly with the long-acting somatostatin analog SMS 201-995

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970062-1

7 January 2021

Preoperative treatment of acromegaly with long-acting somatostatin analog SMS 201-995: shrinkage of invasive pituitary macroadenomas and improved surgical remission rate

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970062-1

7 January 2021

Treatment of resistant acromegaly with a long-acting somatostatin analogue (SMS 201-995).

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970062-1

7 January 2021

SMS 201–995: A very potent and selective octapeptide analogue of somatostatin with prolonged action

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970062-1

7 January 2021

Treatment of macroprolactinomas with the long-acting and repeatable form of bromocriptine: a report on 29 cases

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970062-1

7 January 2021

Epidemiology and long-term survival in acromegaly. A study of 166 cases diagnosed between 1955 and 1984

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970062-1

7 January 2021

Effect of bromocriptine on serum hormones in acromegaly

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970062-1

7 January 2021

Effect of octreotide on gall stone prevalence and gall bladder motility in acromegaly

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970062-1

7 January 2021

Medical treatment of acromegaly with SMS 201-995, a somatostatin analog: a comparison with bromocriptine

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970062-1

7 January 2021

Effects of octreotide on lipid metabolism in acromegaly

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970062-1

7 January 2021

Long-term therapy with long-acting octreotide (Sandostatin-LAR) for the management of acromegaly.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970062-1

7 January 2021

Results of surgical treatment for growth hormone-secreting pituitary adenomas

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970062-1

7 January 2021

Gallstones during octreotide therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970062-1

7 January 2021

A prospective examination of octreotide-induced gall-bladder changes in acromegaly

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970062-1

7 January 2021

Conventional Supervoltage Irradiation Is an Effective Treatment for Acromegaly

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970062-1

7 January 2021

Effects of octreotide on biliary lipid composition and occurrence of cholesterol crystals in patients with acromegaly. A prospective study.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970062-1

7 January 2021

Octreotide treatment of acromegaly. A randomized, multicenter study

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970062-1

7 January 2021

Long-lasting prolactin-lowering effect of cabergoline, a new dopamine agonist, in hyperprolactinemic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970062-1

7 January 2021

Medical treatment of hyperprolactinaemic disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970062-1

7 January 2021

Long-lasting lowering of serum growth hormone and prolactin levels by single and repetitive cabergoline administration in dopamine-responsive acromegalic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970062-1

7 January 2021

Sandostatin LAR in acromegalic patients: a dose-range study

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970062-1

7 January 2021

Long-term endocrinological follow-up evaluation in 115 patients who underwent transsphenoidal surgery for acromegaly

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970062-1

7 January 2021

Short term treatment of acromegaly with the somatostatin analog octreotide: the first double-blind randomized placebo-controlled study on its effects

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970062-1

7 January 2021

Clinical review 22: Therapeutic options in acromegaly

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970062-1

7 January 2021

Hormonal effects of CV 205-502, a novel octahydrobenzo [g] quinoline with potent dopamine agonist properties

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970062-1

7 January 2021

Octreotide long-acting release (LAR). A review of its pharmacological properties and therapeutic use in the management of acromegaly

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970062-1

7 January 2021

Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly: six-month report on an Italian multicenter study. Italian Multicenter Slow Release Lanreotide Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970062-1

7 January 2021

Sandostatin LAR (microencapsulated octreotide acetate) in acromegaly: pharmacokinetic and pharmacodynamic relationships

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970062-1

7 January 2021

Heterogeneous expression of two somatostatin receptor subtypes in pituitary tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970062-1

7 January 2021

A randomized study of SMS 201-995 versus bromocriptine treatment in acromegaly: clinical and biochemical effects

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970062-1

7 January 2021

The combination therapy with bromocriptine and cyproheptadine in patients with acromegaly

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970062-1

7 January 2021

The role of bile composition and physical chemistry in the pathogenesis of octreotide-associated gallbladder stones

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970062-1

7 January 2021

Plasma growth hormone responses to somatostatin (SRIH) and SRIH receptors in pituitary adenomas in acromegalic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970062-1

7 January 2021

Cabergoline treatment of acromegaly: a preliminary dose finding study

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970062-1

7 January 2021

A comparison of octreotide delivered by continuous subcutaneous infusion with intermittent injection in the treatment of acromegaly

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970062-1

7 January 2021

Pergolide for the treatment of pituitary tumors secreting prolactin or growth hormone

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970062-1

7 January 2021

Effect of octreotide on glucose tolerance in acromegaly.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970062-1

7 January 2021

The role of somatostatin in the regulation of anterior pituitary hormone secretion and the use of its analogs in the treatment of human pituitary tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970062-1

7 January 2021

The somatostatin analog SMS 201-995 induces long-acting inhibition of growth hormone secretion without rebound hypersecretion in acromegalic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970062-1

7 January 2021

SMS 201-995 induces a continuous decline in circulating growth hormone and somatomedin-C levels during therapy of acromegalic patients for over two years

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970062-1

7 January 2021

Long-term treatment of acromegaly with the somatostatin analogue SMS 201-995.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970062-1

7 January 2021

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970062-1

1 reference

7 January 2021

A comparison among the growth hormone-lowering effects in acromegaly of the somatostatin analog SMS 201-995, bromocriptine, and the combination of both drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970062-1

7 January 2021

Sandostatin LAR: a promising therapeutic tool in the management of acromegalic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970062-1

7 January 2021

Rapid reduction of left ventricular hypertrophy in acromegaly after suppression of growth hormone hypersecretion

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970062-1

7 January 2021

Decreased plasma growth hormone (GH) levels in acromegalics following CB 154(2-Br-alpha ergocryptine) administration

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970062-1

7 January 2021

Inhibitory effect of L-Dopa on GH release in acromegalic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970062-1

7 January 2021

Cardiovascular aspects in acromegaly: effects of treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970062-1

7 January 2021

Long-term treatment of acromegaly with the slow-release somatostatin analogue lanreotide

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970062-1

7 January 2021

Prolactin-lowering effect of acute and once weekly repetitive oral administration of cabergoline at two dose levels in hyperprolactinemic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970062-1

7 January 2021

A long-term dose-response study of somatostatin analogue (SMS 201-995, octreotide) in resistant acromegaly.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970062-1

7 January 2021

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970062-1

1 reference

7 January 2021

Clinical review 75: Recent advances in pathogenesis, diagnosis, and management of acromegaly

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970062-1

7 January 2021

Bromocriptine therapy in acromegaly: use in patients resistant to conventional therapy and effect on serum levels of somatomedin C

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970062-1

7 January 2021

Use of cabergoline in the long-term treatment of hyperprolactinemic and acromegalic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970062-1

7 January 2021

Effect of CV 205-502 in hyperprolactinaemic patients intolerant of bromocriptine.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970062-1

7 January 2021

Octreotide as primary therapy for acromegaly.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970062-1

7 January 2021

Safety and efficacy of long-term octreotide therapy of acromegaly: results of a multicenter trial in 103 patients--a clinical research center study.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970062-1

7 January 2021

Bromocriptine therapy in acromegaly: effects on plasma GH levels, somatomedin-C levels and clinical activity

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970062-1

7 January 2021

Gastrointestinal side-effects of octreotide during long-term treatment of acromegaly

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970062-1

7 January 2021

Evaluation of a repeatable depot-bromocriptine preparation(Parlodel LAR) for the treatment of acromegaly.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970062-1

7 January 2021

Dose-response study and long term effect of the somatostatin analog octreotide in patients with therapy-resistant acromegaly.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970062-1

7 January 2021

Visualization of somatostatin receptors and correlation with immunoreactive growth hormone and prolactin in human pituitary adenomas: evidence for different tumor subclasses

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970062-1

7 January 2021

The growth hormone responses to octreotide in acromegaly correlate with adenoma somatostatin receptor status

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970062-1

7 January 2021

Gallbladder function in acromegalic patients taking long-term octreotide: evidence of rebound hypermotility on cessation of treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970062-1

7 January 2021

Long-term results of transsphenoidal pituitary microsurgery in 60 acromegalic patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970062-1

7 January 2021

Results of transsphenoidal microsurgery for growth hormone-secreting pituitary adenoma in a series of 214 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970062-1

7 January 2021

Effective clinical response to long term octreotide treatment, with reduced serum concentrations of growth hormone, insulin-like growth factor-I, and the amino-terminal propeptide of type III procollagen in acromegaly

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970062-1

7 January 2021

Effective long-term treatment of acromegaly with a long-acting somatostatin analogue (SMS 201-995).

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970062-1

7 January 2021

Experience of a six-month treatment with sandostatin at increasing doses in acromegaly

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970062-1

7 January 2021

Long term effect of incremental doses of the somatostatin analog SMS 201-995 in 58 acromegalic patients. French SMS 201-995 approximately equal to Acromegaly Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970062-1

7 January 2021

Outcome of transsphenoidal surgery for acromegaly using strict criteria for surgical cure.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970062-1

7 January 2021

Prospective study of the long-term effects of somatostatin analog (octreotide) on gallbladder function and gallstone formation in Chinese acromegalic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970062-1

7 January 2021

Hypopituitarism following radiation therapy of pituitary adenomas

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970062-1

7 January 2021

Presurgical octreotide treatment in acromegaly

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970062-1

7 January 2021

Long term effects of continuous subcutaneous infusion of the somatostatin analog octreotide in the treatment of acromegaly

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970062-1

7 January 2021

Transsphenoidal adenomectomy for growth hormone-secreting pituitary adenomas in acromegaly: outcome analysis and determinants of failure

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970062-1

7 January 2021

Effectiveness of a long‐acting injectable form of bromocriptine in patients with prolactin and growth hormone secreting macroadenomas

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970062-1

7 January 2021

Postprandial gallbladder motility during long term treatment with the long-acting somatostatin analog SMS 201-995 in acromegaly

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970062-1

7 January 2021

Dynamics of the acute effects of octreotide, bromocriptine and both drugs in combination on growth hormone secretion in acromegaly

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970062-1

7 January 2021

Changes in circulating somatomedin-C levels in bromocriptine-treated acromegaly

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970062-1

7 January 2021

A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline Comparative Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970062-1

7 January 2021

10.1016/S0889-8529(05)70062-1

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10207690%20AND%20SRC:MED&resulttype=core&format=json

4 December 2019

1 reference